1-8 of 8
Aino Launonen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Epidemiological Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Use in Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) in Terms of Second Line (2L) Treatment: An Ad Hoc Analysis from the POLARIX Study

Frédéric Boissard, Hervé Tilly, Georg Lenz, Graham P. Collins, Antonio Pinto, Laurie H. Sehn, Gilles Salles, Mathilde Roussel, Leonardo Simonella, Rodrigo Ho, Jamie Hirata, Calvin Lee, Anthony Masaquel, Aino Launonen
Journal: Blood
Blood (2022) 140 (Supplement 1): 6645–6647.
https://doi.org/10.1182/blood-2022-157904
Published: 2022
Journal Articles

Exploring the Impact of Diffuse Large B-Cell Lymphoma (International Prognostic Index [IPI] 2-5) on Clinical and Patient-Relevant Outcomes in the Context of a Clinical Trial

Aino Launonen, Rodrigo Ho, Andrea Knapp, Irene Canales Ruiz, Leonardo Simonella, Per-Olof Thuresson
Journal: Blood
Blood (2021) 138 (Supplement 1): 3577.
https://doi.org/10.1182/blood-2021-146822
Published: 2021
Journal Articles

Comparative Effectiveness of Bendamustine Plus Rituximab (BR) and Rituximab Plus Gemcitabine and Oxaliplatin (R-GemOx) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Felipe Castro, Andy Surinach, MPH, Aino Launonen, Per-Olof Thuresson, Federico Felizzi
Journal: Blood
Blood (2020) 136 (Supplement 1): 41–42.
https://doi.org/10.1182/blood-2020-137529
Published: 2020
Journal Articles

Risk Factors and Outcomes of Patients with Follicular Lymphoma Who Had Histologic Transformation at First Progression after First-Line Immunochemotherapy in the Gallium Study

Carla Casulo, Michael Herold, MD, Wolfgang Hiddemann, MD PhD, Sunil Iyengar, MD, Robert E. Marcus, FRCP, John F. Seymour, MBBS, PhD FRACP, Aino Launonen, MSc, Andrea Knapp, PhD, Tina G Nielsen, MD PhD, Farheen Mir, MBBS, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5268.
https://doi.org/10.1182/blood-2019-123466
Published: 2019
Journal Articles

Quality of Life (QoL) in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (NHL) Treated with Polatuzumab Vedotin Plus Rituximab in the ROMULUS Study

Per-Olof Thuresson, MSc, MPharm, Brittany Gentile, PhD, David Ramies, MD, Aino Launonen, MSc, Franck Morschhauser, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4767.
https://doi.org/10.1182/blood-2019-123688
Published: 2019
Journal Articles

A Novel Prognostic Model That Is Superior to FLIPI-1 and FLIPI-2 and Integrates Clinical and Treatment Factors to Predict Progression-Free Survival and Early Treatment Failure in Patients with Follicular Lymphoma in the GALLIUM Trial

Farheen Mir, MBBS, Andrew Grigg, Michael Herold, Wolfgang Hiddemann, Robert Marcus, John F. Seymour, MBBS, PhD, Christopher R Bolen, Andrea Knapp, Aino Launonen, Federico Mattiello, Tina Nielsen, Mikkel Z Oestergaard, Michael Wenger, Carla Casulo, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2872.
https://doi.org/10.1182/blood-2018-99-114620
Published: 2018
Journal Articles

No Added Benefit of Eight Versus Six Cycles of CHOP When Combined with Rituximab in Previously Untreated Diffuse Large B-Cell Lymphoma Patients: Results from the International Phase III GOYA Study

Laurie H Sehn, MDMPH, Angela Giovanna Congiu, Dominic J. Culligan, Mercedes Gironella, Dok Hyun Yoon, Michinori Ogura, Andras Rosta, Jun Zhu, Aino Launonen, Tina Nielsen, Gila Sellam, Marek Trněný, Umberto Vitolo, Maurizio Martelli
Journal: Blood
Blood (2018) 132 (Supplement 1): 783.
https://doi.org/10.1182/blood-2018-99-116845
Published: 2018
Journal Articles

Early Disease Progression Predicts Poorer Survival in Patients with Follicular Lymphoma (FL) in the GALLIUM Study

Aino Launonen, Wolfgang Hiddemann, MD PhD, Ulrich Duenzinger, Günter Fingerle-Rowson, Tina Nielsen, Robert Marcus
Journal: Blood
Blood (2017) 130 (Supplement 1): 1490.
https://doi.org/10.1182/blood.V130.Suppl_1.1490.1490
Published: 2017